Overview
Invasive carcinoma of the urinary bladder is a malignant neoplasm that has invaded through the basement membrane into deeper bladder wall layers, posing significant oncological challenges due to potential for metastasis and poor prognosis compared to non-invasive forms 1.Diagnosis
Cystoscopy with biopsy for histopathological confirmation 1.
Imaging studies including CT urography or MRI to assess tumor extent and regional lymph nodes 1.
Urine cytology to detect malignant cells 1.
Grading based on WHO classification: high-grade (G3) or low-grade (G1/G2) 1.Management
Surgery: Radical cystectomy with pelvic lymphadenectomy for localized disease 1.
Neoadjuvant therapy: Consideration for high-risk patients to downstage tumors before surgery 1.
Adjuvant chemotherapy: For high-risk features post-surgery, such as lymph node involvement (e.g., MVAC regimen) 1.
Radiation therapy: For patients unfit for surgery or as adjuvant/salvage treatment 1.Special Populations
Elderly: Tailored treatment approaches considering comorbidities and functional status; radical cystectomy may be less feasible 1.
Comorbidities: Management strategies adjusted based on coexisting conditions, potentially favoring less invasive or systemic treatments 1.Key Recommendations
Utilize multimodal approaches including surgery, chemotherapy, and radiation therapy based on tumor stage and patient fitness 1 (Evidence: Strong).
Consider neoadjuvant therapy in high-risk invasive bladder cancer to improve outcomes 1 (Evidence: Moderate).
Tailor treatment plans for elderly patients and those with significant comorbidities, prioritizing quality of life and functional outcomes 1 (Evidence: Expert opinion).References
1 Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D et al.. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology 2014. link